Ludwig Hantson, Alexion via Twitter
January 6, 2021 09:08 AM EST
Deals
Pharma

So why is Alex­ion pay­ing $100M for a PRV as As­traZeneca lines up their $39B buy­out?

John Carroll

Editor & Founder

It looks like As­traZeneca may have a bonus wait­ing once it’s done ac­quir­ing Alex­ion.

Yes­ter­day, Rhythm Phar­ma­ceu­ti­cals put out word that the biotech sold …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

A service from the Financial Times